HelixBind Awarded $3MM Grant from NIH for New Rapid Test for the Early Detection of Lyme Disease
16 juil. 2020 12h01 HE
|
HelixBind
BOXBOROUGH, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for patients afflicted with invasive microbial infections,...
HelixBind Awarded $3MM Grant from NIH and Expands Clinical Advisory Board to Accelerate Development of Its Diagnostic Platform for Invasive Infections
10 juin 2020 10h29 HE
|
HelixBind
BOXBOROUGH, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
Phase Genomics Receives $1.5MM NIH Grant to Develop Fast and Affordable Commercial Antimicrobial Resistance Tracking Kit
08 janv. 2020 09h30 HE
|
Phase Genomics
SEATTLE, Washington, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Phase Genomics, Inc., the biotech leader providing proximity-ligation next-generation sequencing (NGS) solutions for metagenome assembly, today...
Allecra Therapeutics to Present Data at ASM/ESCMID 2019 Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
03 sept. 2019 07h00 HE
|
Allecra Therapeutics GmbH
LÖRRACH, Germany and SAINT-LOUIS, France, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Allecra Therapeutics (Private), a biopharmaceutical company focused on developing and commercializing novel...
BioAegis Therapeutics Reports Favorable Safety and Pharmacokinetic Results in its Phase 1b/2a Dose-Escalation Study of Recombinant Human Plasma Gelsolin with Highest Doses Ever Administered to Patients
07 août 2019 10h00 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc. announced the major findings from its Phase 1b/2a study of Recombinant Human Plasma Gelsolin for patients requiring...
DNV GL Healthcare Focuses on Overcoming Antimicrobial Resistance in Nation's Hospitals
29 mai 2019 16h27 HE
|
DNV GL Business Assurance USA, Inc.
MILFORD, OHIO, May 29, 2019 (GLOBE NEWSWIRE) -- As the Centers for Disease Control and Prevention (CDC) ramps up the nation’s attempts to neutralize antibiotic/anti-microbial resistance (AMR) in...
Louisiana Restaurants to Disclose Use of Foreign Shrimp and Crawfish
29 mai 2019 13h28 HE
|
American Shrimp Processors Association
BILOXI, Miss., May 29, 2019 (GLOBE NEWSWIRE) -- In a move to protect Louisiana consumers from “the health risks associated chemicals and residues in imported seafood,” the Louisiana Senate...
BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
18 mars 2019 11h00 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN)...
Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
14 mars 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at...
BioAegis Therapeutics Expands Phase 1b/2a Community-Acquired Pneumonia Study to the Republic of Georgia —Successfully Completes Second of Four Dosing Cohorts
07 févr. 2019 09h17 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that patient enrollment is underway in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in...